Genomic Health announced that Phill Febbo has joined the firm as its new chief medical officer. Febbo is an experienced physician scientist who was previously a professor of medicine and urology at the University of California, San Francisco. He will report to Steve Shak, Genomic Health's executive VP of R&D.
Additionally, Henry Fuchs, executive VP and CMO of Biomarin, has joined Genomic Health's board of directors. He has previously held leadership roles at Onyx and Genentech.
Woodrow Myers, managing director of Myers Ventures, will step down from his seven-year tenure on Genomic Health's board. Myers will now be CEO of Corizon, a provider of correctional healthcare services.
Oxford Gene Technology has named Bob Holland to be its new chief medical officer, the company said this week. Holland helped to create and was VP and head of AstraZeneca's Personalized Healthcare and Biomarkers division. In his new role, Holland will lead clinical affairs across OGT's business areas, including working with R&D and commercial teams to develop clinical development programs to expand the company's next-generation sequencing and microarray cancer profiling solutions, and its biomarker programs for prostate and colorectal cancers.